Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

A wortmannin-cetuximab as a double drug.

Smith RA, Yuan H, Weissleder R, Cantley LC, Josephson L.

Bioconjug Chem. 2009 Nov;20(11):2185-9. doi: 10.1021/bc900176a.

2.

Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.

Junutula JR, Flagella KM, Graham RA, Parsons KL, Ha E, Raab H, Bhakta S, Nguyen T, Dugger DL, Li G, Mai E, Lewis Phillips GD, Hiraragi H, Fuji RN, Tibbitts J, Vandlen R, Spencer SD, Scheller RH, Polakis P, Sliwkowski MX.

Clin Cancer Res. 2010 Oct 1;16(19):4769-78. doi: 10.1158/1078-0432.CCR-10-0987.

3.

Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.

Bijman MN, van Berkel MP, Kok M, Janmaat ML, Boven E.

Anticancer Drugs. 2009 Jul;20(6):450-60. doi: 10.1097/CAD.0b013e32832afc24.

PMID:
19369859
4.

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.

Behrens CR, Ha EH, Chinn LL, Bowers S, Probst G, Fitch-Bruhns M, Monteon J, Valdiosera A, Bermudez A, Liao-Chan S, Wong T, Melnick J, Theunissen JW, Flory MR, Houser D, Venstrom K, Levashova Z, Sauer P, Migone TS, van der Horst EH, Halcomb RL, Jackson DY.

Mol Pharm. 2015 Nov 2;12(11):3986-98. doi: 10.1021/acs.molpharmaceut.5b00432.

PMID:
26393951
5.

[Anti-angiogenic effect of vinorelbine in combination with cetuximab in vitro and in vivo].

Qian XP, Liu BR, Wan L, Hu J, Zhu LJ, Yu LX.

Zhonghua Zhong Liu Za Zhi. 2010 Apr;32(4):253-7. Chinese.

PMID:
20510073
6.

Design and development of masked therapeutic antibodies to limit off-target effects: application to anti-EGFR antibodies.

Donaldson JM, Kari C, Fragoso RC, Rodeck U, Williams JC.

Cancer Biol Ther. 2009 Nov;8(22):2147-52.

7.

Different antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathway.

Meira DD, Nóbrega I, de Almeida VH, Mororó JS, Cardoso AM, Silva RL, Albano RM, Ferreira CG.

Eur J Cancer. 2009 May;45(7):1265-73. doi: 10.1016/j.ejca.2008.12.012.

PMID:
19167213
8.

In vitro and in vivo antitumor activity of immunoconjugates prepared by linking 5-fluorouridine to antiadenocarcinoma monoclonal antibody.

Brusa P, Dosio F, Coppo S, Pacchioni D, Arpicco S, Crosasso P, Cattel L.

Farmaco. 1997 Feb;52(2):71-81.

PMID:
9181686
9.

Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.

Milenic DE, Wong KJ, Baidoo KE, Ray GL, Garmestani K, Williams M, Brechbiel MW.

Cancer Biother Radiopharm. 2008 Oct;23(5):619-31. doi: 10.1089/cbr.2008.0493.

10.

Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.

Park SJ, Kim MJ, Kim YK, Kim SM, Park JY, Myoung H.

Cancer Lett. 2010 Jun 1;292(1):54-63. doi: 10.1016/j.canlet.2009.11.004.

PMID:
19959278
11.

Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.

Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.

J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.

PMID:
16288119
12.

Does dexamethasone inhibit anticancer activity of cetuximab in squamous cell carcinoma cell lines of the head and neck?

Wagenblast J, Baghi M, Mörtel S, Hirth D, Thron L, Arnoldner C, Gstöttner W, May A, Hambek M.

Oncol Rep. 2009 Jul;22(1):171-6.

PMID:
19513520
13.

Enhancement of tumor uptake and therapeutic efficacy of EGFR-targeted antibody cetuximab and antibody-drug conjugates by cholesterol sequestration.

Chen Y, Liu G, Guo L, Wang H, Fu Y, Luo Y.

Int J Cancer. 2015 Jan 1;136(1):182-94. doi: 10.1002/ijc.28950.

14.

Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.

Quesnelle KM, Wheeler SE, Ratay MK, Grandis JR.

Cancer Biol Ther. 2012 Aug;13(10):935-45. doi: 10.4161/cbt.20846.

15.

The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP.

Li JJ, Ding Y, Li DD, Peng RQ, Feng GK, Zeng YX, Zhu XF, Zhang XS.

Cancer Biol Ther. 2009 Oct;8(20):1914-21.

PMID:
20009541
16.
17.
18.

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.

Wheeler DL, Huang S, Kruser TJ, Nechrebecki MM, Armstrong EA, Benavente S, Gondi V, Hsu KT, Harari PM.

Oncogene. 2008 Jun 26;27(28):3944-56. doi: 10.1038/onc.2008.19.

19.

Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin.

Wipf P, Minion DJ, Halter RJ, Berggren MI, Ho CB, Chiang GG, Kirkpatrick L, Abraham R, Powis G.

Org Biomol Chem. 2004 Jul 7;2(13):1911-20.

PMID:
15227545
20.

Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

Mukohara T, Engelman JA, Hanna NH, Yeap BY, Kobayashi S, Lindeman N, Halmos B, Pearlberg J, Tsuchihashi Z, Cantley LC, Tenen DG, Johnson BE, Jänne PA.

J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94.

PMID:
16106023

Supplemental Content

Support Center